Switching From Zepbound to Wegovy (and Back): An Honest Guide

People switch between Zepbound and Wegovy all the time — usually not because one stopped working, but because insurance changed, a coupon expired, a pharmacy ran short, or the side effects on one were rougher than the other. Whatever the reason, the single most important thing to understand before you switch is this: these are two different drugs, and the doses do not convert one-to-one. There is no validated "5 mg of this equals so-many milligrams of that" chart. A safe switch is re-titrated from a low starting dose and led by your prescriber, not copied across at the same number.

This guide walks through what the two drugs actually are, why a switch means re-starting the dose ladder rather than swapping like-for-like, the common real-world reasons people move, and what to realistically expect — appetite, side effects, and weight — in the weeks after. It is general health information, not medical advice; both medicines are prescription-only and any switch should be a conversation with the clinician who prescribed them.

Zepbound and Wegovy are not the same molecule

This is the foundation everything else rests on. Wegovy is semaglutide. It is a single-receptor drug: a GLP-1 receptor agonist. Zepbound is tirzepatide. It is a dual-receptor drug, acting on both the GLP-1 receptor and the GIP receptor. They are made by different companies (Wegovy by Novo Nordisk, Zepbound by Eli Lilly), approved under separate FDA labels, and titrated on completely different milligram scales.

You can see the mismatch in the numbers themselves. Per its FDA label, Wegovy steps up through 0.25, 0.5, 1.0, 1.7, and a 2.4 mg maintenance dose⁸. Zepbound steps up through 2.5, 5, 7.5, 10, 12.5, and 15 mg⁹. The milligram figures are not comparable — a "5" on one is not a "5" on the other, because they are different chemicals at different potencies hitting different receptors. That is exactly why no honest source publishes a direct conversion table. (If the same-molecule-different-brand idea is new to you, our explainer on Ozempic vs Wegovy shows how brand names map to molecules.)

Why a switch means re-titrating, not copying the dose

When you start either of these drugs from scratch, you don't begin at the top. You begin low and climb slowly — and that slow climb exists for a reason. The dominant side effects of both medicines are gastrointestinal: nausea, vomiting, diarrhea, and constipation, driven largely by slowed gastric emptying. The escalation schedule is the main tool clinicians use to keep those side effects tolerable, and the data back that up: in a dedicated analysis of semaglutide 2.4 mg, GI events clustered during dose escalation, were mostly mild-to-moderate and transient, and the gradual step-up was central to managing them⁷.

Because the molecules differ, your stomach has no guarantee of tolerating an "equivalent-feeling" dose of the new drug just because you tolerated a high dose of the old one. So the standard, cautious approach when switching is to re-start near the bottom of the new drug's ladder and titrate up again — even if you were comfortable at a high dose of the previous medicine. It can feel like starting over, and sometimes it slows things down temporarily, but it is how you avoid trading a coverage problem for a week of misery. The exact starting point and pace are a clinical judgment call based on how long you were on the prior drug, how you tolerated it, and your prescriber's read of your situation. There is no validated shortcut. (For how the dose ladder and side effects work on the semaglutide side specifically, see semaglutide dosing and side effects.)

One practical timing point: both drugs are once-weekly injections. A common pattern is to start the new medicine roughly one week after the last dose of the old one — but the precise gap is, again, a clinician-led decision, not a rule to self-apply.

Does the switch cost you weight loss? What the head-to-head shows

This is the question most people actually care about, and here the evidence is unusually clear because the two drugs were finally compared directly. In SURMOUNT-5, a head-to-head randomized trial, tirzepatide (Zepbound) produced greater average weight loss than semaglutide (Wegovy) — roughly 20% versus about 14% of body weight over 72 weeks at maximum tolerated doses¹. That result is consistent with the separate pivotal trials: semaglutide 2.4 mg delivered about 15% mean weight loss in STEP-1², while tirzepatide reached up to roughly 21% at its highest dose in SURMOUNT-1³.

So, read honestly: on average, tirzepatide drives more weight loss than semaglutide. Switching from Zepbound to Wegovy may mean a somewhat smaller average effect, and switching the other way may mean a somewhat larger one. But "on average" is doing real work in that sentence — these are population means, and individual response varies widely. Plenty of people do very well on semaglutide; some tolerate it far better than tirzepatide. The trial averages tell you the central tendency, not your personal outcome. For a dedicated head-to-head of the two molecules — weight loss, side effects, and cardiovascular evidence — see semaglutide vs tirzepatide: which works better?. For the fuller picture of what semaglutide does and doesn't do, see our pillar, how semaglutide works: results and side effects.

It is also worth remembering that weight loss isn't the only outcome that matters. Semaglutide has a distinct, FDA-recognized cardiovascular benefit: in the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity but without diabetes⁴. We cover that in detail in do Wegovy and Ozempic protect the heart? — it can be a genuine reason a clinician favors the semaglutide side for a specific patient. The reverse is true for sleep apnea: only tirzepatide (Zepbound) is FDA-approved to treat obstructive sleep apnea, so switching to Wegovy means giving up that on-label indication — see does Wegovy or Ozempic help sleep apnea?.

The common, honest reasons people switch

Switching is rarely about chasing the "best" drug in the abstract. The real-world drivers are usually:

• •Cost and coupons. Self-pay prices, savings-card eligibility, and manufacturer offers shift over time, and a change can flip which drug is affordable this month. We track the semaglutide side in our Wegovy cost and savings guide.
• •Insurance and coverage. A formulary change, a denied prior authorization, or a new plan can suddenly cover one drug and not the other. (Our does insurance cover Wegovy or Ozempic? walks through how that plays out.)
• •Supply and shortage. Both drugs have spent time on the FDA shortage list; intermittent availability pushes people to whatever they can actually fill.
• •Tolerability. Some people simply feel less nauseated on one molecule than the other — a legitimate medical reason to switch, and one your prescriber can help you weigh.
• •Efficacy or plateau. If results stall or fall short of goals, a clinician may suggest moving to the drug with the larger average effect. (Note that "switching back" — Wegovy to Zepbound — is just as common, and the same re-titration logic applies in reverse.)

None of these reasons is wrong. The point is just that the decision and the dose both belong with your clinician.

What to expect after you switch

Plan for an adjustment period, not a seamless handoff. Because you are re-titrating, the first few weeks on the new drug may feel like the early weeks of your original one: some appetite suppression building back up, possibly some GI side effects as your body re-adjusts, and weight change that may pause or wobble before re-establishing a trend. That is normal and expected, given the escalation schedule — not a sign the new drug "isn't working." Tell your prescriber if side effects are severe or persistent rather than pushing through.

There is also a stopping-the-old-drug consideration baked into any switch: appetite and weight regain are real when GLP-1-class therapy is paused. In the semaglutide withdrawal trial STEP-4, people who stopped semaglutide regained a substantial share of lost weight⁵; the tirzepatide maintenance trial SURMOUNT-4 showed the same pattern — continued treatment maintained the loss, while stopping led to regain⁶. A well-managed switch minimizes the off-drug gap precisely so you don't slide backward during the transition. (For what stopping looks like in general, see what happens if you stop semaglutide?.)

The bottom line

Switching between Zepbound and Wegovy is common and often the right call — but it is a clinician-led, re-titrated change, not a same-number swap. The two drugs are different molecules on different milligram scales, so there is no validated conversion; the safe approach is to re-start the new drug's dose ladder from low and climb. On average, tirzepatide produces more weight loss than semaglutide (SURMOUNT-5), but individual response varies, semaglutide carries its own cardiovascular benefit, and the best choice depends on cost, coverage, supply, tolerability, and your own goals. Both are prescription-only; have the conversation with your prescriber before you change anything. To compare your real options on price and oversight, see our best semaglutide providers roundup.